Skip to content

Study · Observational study · 2021

3 results

The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.

Koochaki P, Revicki D, Wilson H, Pokrzywinski R, Jordan R, Lucas J, Williams LA, Sadiq A, Krop J

Journal of women's health (2002)3 Feb 2021Cited by 9 (Europe PMC)

PMID33538638 (opens in a new tab)DOI10.1089/jwh.2020.8460 (opens in a new tab)PepBankPUB-33538638
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In premenopausal women with HSDD, participants who received bremelanotide described increased feelings of sexual desire in exit surveys and interviews.

    In plain wordsIn women with low sexual desire, those given bremelanotide described more sexual desire when asked at the end of the trials.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreasePatient-reported sexual desire (exit survey and interviews)
    Study

    n: not reported in source

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Participants who received bremelanotide described increased feelings of sexual desire, physical arousal, and improvements in overall quality of their sexual activities in their partner relationship.
    1 context sentence
    Summary · context
    Quantitative exit surveys were completed by 242 RECONNECT participants; 80 of these women also completed qualitative telephone exit interviews.
  2. 02HumanObservational studyEfficacy outcome

    In premenopausal women with HSDD, participants who received bremelanotide described increased physical arousal in exit surveys and interviews.

    In plain wordsIn women with low sexual desire, those given bremelanotide described more physical arousal when asked at the end of the trials.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreasePatient-reported physical arousal (exit survey and interviews)
    Study

    n: not reported in source

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Participants who received bremelanotide described increased feelings of sexual desire, physical arousal, and improvements in overall quality of their sexual activities in their partner relationship.
    1 context sentence
    Summary · context
    Quantitative exit surveys were completed by 242 RECONNECT participants; 80 of these women also completed qualitative telephone exit interviews.
  3. 03HumanObservational studyEfficacy outcome

    In premenopausal women with HSDD, participants who received bremelanotide described improvements in the overall quality of their sexual activities in their partner relationship.

    In plain wordsIn women with low sexual desire, those given bremelanotide described better quality of sexual activity with their partner at the end of the trials.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreasePatient-reported quality of sexual activities (exit survey and interviews)
    Study

    n: not reported in source

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Participants who received bremelanotide described increased feelings of sexual desire, physical arousal, and improvements in overall quality of their sexual activities in their partner relationship.
    1 context sentence
    Summary · context
    Quantitative exit surveys were completed by 242 RECONNECT participants; 80 of these women also completed qualitative telephone exit interviews.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02338960

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Palatin Technologies, Incn = 714Jan 2015 to 29 Jun 2017

Hypoactive Sexual Desire Disorder

Trial pageClinicalTrials.govUpdated 28 Jan 2021
CompletedPhase 3Results postedNCT02333071

1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Palatin Technologies, Incn = 723Dec 2014 to 30 Jun 2017

Hypoactive Sexual Desire Disorder

Trial pageClinicalTrials.govUpdated 9 Apr 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.